tirzepatide nejm In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https://nej.md/4hRGaTY Medthreads Tirzepatide vs Semaglutide: 2025 NEJM

If you become pregnant while using Shed tirzepatide, discontinue the medication and inform your healthcare provider immediately

Dosage Take up to 3 veg

Unlike semaglutide, which only targets GLP-1 receptors, tirzepatide is a dual agonist that targets GLP-1 and glucagon receptors

Thus, BPC 157 does not act as a serotonin substrate

STEP (obesity, no diabetes required) The pivotal obesity trial, STEP-1 , was published as Wilding et al., NEJM 2021, PMID 33567185

Importantly, 100% of participants receiving the 12 mg dose achieved at least 5% weight loss, while 91% achieved 10% or greater reduction, and 75% reached the clinically significant threshold of 15% weight loss